OFIX earnings

  Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, incre

Company to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Informati

Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountability, and further advance commercialization of the 7D™ navigation platform, Orthofix has streamlined its Spine organization by eliminating the rol

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-year 2026 financial guidance and updated its three-year financial targets. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Fourth quarter reported 2025 net sales of $219.9 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales of $218.6 million, excluding sales from M6 discs, representing an increase of 2% on a reported basis and 3% on a non-GAAP pr

Company to Host Conference Call on Tuesday, February 24, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 2236604. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. In

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter 2025 net sales of $205.6 million, including sales from M6 artificial cervical and lumbar discs, and pro forma net sales of $203.4 million, excluding sales from M6 discs, representing an increase of 5% on a reported basis and 6% on a

Company to Host Conference Call on Tuesday, November 4, 2025, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 5112586. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs, and pro forma net sales of $200.7 million, excluding sales from M6® discs, representing an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to second quarter 2024 U.S. Spine

Company to Host Conference Call on Tuesday, August 5, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 4830464. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Info

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account

Company to Host Conference Call on Tuesday, February 25, 2025 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the event passcode 5184023. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Post

Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of 18% compared to third quarter 2023, driven by distribution expansion and further penetration in existi

Company to Host Conference Call on Thursday, November 7, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,

Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on

Company to Host Conference Call on Tuesday, August 6, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,

Recent Highlights Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 16%, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on a reported basis, primarily driven by U.S. Orthopedic net sales growth of 23% First quarter 2024 net loss of $36 million; Non-GAAP Adjusted EBITDA of $8 million, an increase of $4.5 million, a 220 basis point expansion over prior year Midpoint of full

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and

Recent Highlights Fourth quarter 2023 net sales of $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis Bone Growth Therapies net sales growth of 15% for the fourth quarter of 2023, marking four consecutive quarters with double-digit net sales increases, representing the strongest quarter of Bone Growth Therapies sales in the history of Orthofix U.S. Orthopedic net sales growth of 11% for the full year 2023 U.S. spine fixation1 net sales growth of 13.5% in Q4 2023 with net distributor additions since the third quarter of 2023 Fourth quarter 2023 net loss of $22 million; Non-GAAP Adjusted EBITDA of $20 million, or 10% of sales, r

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the co

In November 2023, entered into a new four-year financing agreement with borrowing capacity of up to $150 million Net sales of $184.0 million, an increase of 61% on a reported basis and an increase of 8% on a pro forma basis when normalizing for a one-time stocking order that occurred in the third quarter of 2022 for SeaSpine Bone Growth Therapies growth of 15%, marking three consecutive quarters with double-digit net sales increases, with growth coming from both spine and fracture portfolios U.S. spinal implants, biologics, and enabling technologies sales growth of 7% on a pro forma basis over prior year Global Orthopedics net sales increase of 7% on a reported basis over prior

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference c

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call

Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year Bone Growth Therapies growth of 14%, with growth coming from both spine and fracture commercial channels U.S. spinal implant sales up 18% over prior year on a pro forma basis, driven by new distribution and product innovation Continued double-digit growth in Global Orthopedics over prior year on a constant currency basis Announced the full commercial launch of the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, which addresses an estimated $1.8 billion market related to minimally invasive spine procedures Orthofix Me

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2023 financial results on Tuesday, May 9, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and

(NASDAQ:OFIX) The merger of Orthofix Medical Inc. ("Orthofix") and SeaSpine Holdings Corporation ("SeaSpine") became effective as of January 5, 2023. This news release includes the financial results of stand-alone Orthofix and stand-alone SeaSpine for the fourth quarter and full year ended December 31, 2022. As such, these financial results do not include any potential accounting adjustments the merger may have on future net sales or operating results. Orthofix Fourth Quarter Highlights Net sales of $122.2 million, a decrease of 2% on a reported basis and flat on a constant currency basis over prior year Bone Growth Therapies net sales growth of approximately 3%, driven by the commerci

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter 2022 financial results of stand-alone Orthofix as well as stand-alone SeaSpine, which was merged into Orthofix effective January 5, 2023, on Monday, March 6, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and

Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year Global Orthopedics net sales growth of 19% on a constant currency basis driven by new product and channel investments GAAP EPS of ($0.53) and adjusted EPS of $0.13 Orthofix and MTF Biologics recognized with the 2022 Spine Technology Award from Orthopedics This Week for Virtuos™ Lyograft, the first of its kind, shelf-stable and complete autograft substitute Announced agreement to merge with SeaSpine, creating a leading global spine and orthopedics company Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its third quarter 2022 financial results before market open on Thursday, November 3, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S.,

Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

Net sales of $118.1 million, a decrease of 3% on a reported basis and flat on a constant currency basis over prior year Global Orthopedics net sales growth of 11% on a constant currency basis driven by new products and channel investments GAAP EPS of $0.12 and adjusted EPS of $0.08 Executed partnership with CGBio to commercialize Novosis™ rhBMP-2 growth factor in the U.S. and Canada Limited launch of Virtuos™ Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute Full year revenue guidance of $455 to $465, which represents flat to 2% growth on a constant currency basis over prior year Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial result

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its second quarter 2022 financial results before market open on Friday, August 5, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (844) 200-6205 in the U.S. and Canada, and (929) 526-1599 all other locations, and referencing the access code 135199. A replay of the call will be available for three weeks by dialing (866) 813-9403 in the U.S.

Net sales of $106.4 million, an increase of 1% on a reported basis and 2% on a constant currency basis over prior year New product sales drive solid growth in Biologics, Spinal Implants, and Orthopedics FDA grants PMA for AccelStim™ bone growth stimulator — LIPUS technology expands our indications into fresh fracture care FDA clearance received for the TrueLok™ EVO Ring Fixation system, which enables clear radiographic visualization Reaffirming 2022 guidance Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2022. Net sales were $106.4 million, earnings per share ("EPS") was $(0.22), and adjusted EPS was $(0.10). "We're very

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the first quarter 2022 before market open on Friday, May 6, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (844) 200-6205 in the U.S., (833) 950-0062 in Canada and (929) 526-1599 all other locations, and referencing the access code 428610. A replay of the call will be available for three weeks by dialing (866) 81

Fourth quarter net sales of $125.1 million, an increase of 6% over the prior year 2021 annual net sales of $464.5 million, an increase of 14% over the prior year Double-digit net sales growth in the quarter and for the year compared to the prior year period for both global Spinal Implants and Orthopedics Entered into a partnership and investment with nView medical, developer of novel imaging and guidance systems Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. Net sales for the fourth quarter were $125.1 million, earnings (loss) per share ("EPS") was $(1.65) and adjusted EPS was $0.27. For fisca

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the fourth quarter and full year 2021 before market open on Friday, February 25, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (844) 200-6205 in the U.S., (833) 950-0062 in Canada and (929) 526-1599 all other locations, and referencing the access code 918184. A replay of the call will be available for three week

Fourth quarter net sales of approximately $125 million, an increase of 11% sequentially and 6% versus the prior year 2021 annual net sales of approximately $464 million, an increase of 14% versus the prior year Double-digit growth over the prior year period for both global Spinal Implants and Orthopedics for the third consecutive quarter Double-digit net sales growth across all product categories sequentially versus the third quarter Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2021 net sales of approximately $125 million, an increase of 6% on a reported basis and 7% on a constant currency basis versus fourth quarter 2020. On a sequential

Net sales of $112 million, an increase of 1.3% over the prior year period Double-digit growth over the prior year period for both global Spinal Implants and Orthopedics More than 1,000 U.S. surgeons trained and 60,000 M6-C artificial cervical discs implanted worldwide to date Launched Opus Mg Set synthetic bone void filler Submitted AccelStim PMA application for the healing of fresh fractures Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2021. Net sales were $112 million, earnings per share ("EPS") was $(0.11), and adjusted EPS was $0.10. "I am proud of the tenacity of our team as they continue to implement our strat

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the third quarter 2021 before market open on Friday, November 5, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (833) 670-0709 in the U.S. and (343) 761-2533 outside the U.S., and referencing the conference ID 1889020. A replay of the call will be available for three weeks by dialing (800) 585-8367 in the U.S. or

Net sales of $121 million, up 66% compared to prior year and 5% compared to the second quarter of 2019 U.S. Spinal Implants net sales grew 56% compared to prior year and 37% over the second quarter of 2019 Strong performance from our U.S. M6-C™ artificial cervical disc and FITBONE® limb lengthening system with approximately $9 million in combined sales Company raises full year 2021 revenue and adjusted EBITDA guidance Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2021. Net sales were $121 million, earnings per share ("EPS") was $0.12, and adjusted EPS was $0.32. "We are proud of our second quarter performance, in which we

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the second quarter 2021 before market open on Friday, August 6, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (833) 670-0709 in the U.S. and (343) 761-2533 outside the U.S., and referencing the conference ID 4363197. A replay of the call will be available for three weeks by dialing (800) 585-8367 in the U.S. or